Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.54 |
| ▸ | SGMS2 | Q8NHU3 | 1/20 | 0.51 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.47 |
| ▸ | MET | P08581 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18997912 | 0.92 | MEN1 (0.56) | MEN1KMT2ASGMS2KCNK3KCNK9 | |
| SCHEMBL19049633 | 0.86 | SMN1; SMN2 (0.61) | MEN1KMT2ASGMS2KCNK3KCNK9 | |
| SCHEMBL21776427 | 0.86 | MEN1 (0.57) | MEN1KMT2ASGMS2KCNK3KCNK9 | |
| SCHEMBL21740962 | 0.84 | MEN1 (0.57) | MEN1KMT2ASGMS2KCNK3KCNK9 | |
| SCHEMBL16941524 | 0.81 | MEN1 (0.69) | MEN1KMT2AKCNK3KCNK9NPSR1 | |
| SCHEMBL26162537 | 0.81 | MEN1 (0.56) | MEN1KMT2ASGMS2KCNK3KCNK9 | |
| SCHEMBL15614717 | 0.76 | RXFP1 (0.74) | RXFP1 | |
| SCHEMBL19002715 | 0.76 | MEN1 (0.56) | MEN1KMT2ASGMS2KCNK3KCNK9 | |
| SCHEMBL18997919 | 0.72 | SPHK1 (0.56) | MEN1KMT2ASGMS2AURKAAURKB | |
| SCHEMBL13812767 | 0.72 | KCNK3 (0.54) | MEN1KMT2AKCNK3KCNK9LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2020-12-22 | — | — | US | disclosed |
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | SHY Therapeutics LLC | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190218229-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMTORY DISEASE | MAPK1, MAPK6, MAP3K1 | MEN1 3536/4885KMT2A 3181/4885SGMS2 600/4885 |
| US-10870657-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | MEN1 4080/4885KMT2A 3544/4885SGMS2 586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.